{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T23:20:19Z","timestamp":1791156019860,"version":"4.1.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2004,5,1]],"date-time":"2004-05-01T00:00:00Z","timestamp":1083369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2004,5]]},"DOI":"10.1053\/j.gastro.2004.02.070","type":"journal-article","created":{"date-parts":[[2005,7,29]],"date-time":"2005-07-29T18:31:14Z","timestamp":1122661874000},"page":"1593-1610","source":"Crossref","is-referenced-by-count":347,"title":["Optimizing anti-TNF treatment in inflammatory bowel disease"],"prefix":"10.1053","volume":"126","author":[{"given":"Paul","family":"Rutgeerts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert","family":"van Assche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9verine","family":"Vermeire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2004.02.070_BIB1","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/gut.35.3.360","article-title":"Frequency of glucocorticoid resistance and dependency in Crohn\u2019s disease","volume":"35","author":"Munkholm","year":"1994","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2004.02.070_BIB2","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1053\/gast.2001.26279","article-title":"The natural history of corticosteroid therapy for inflammatory bowel disease","volume":"121","author":"Faubion","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2004.02.070_BIB3","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1136\/gut.39.1.82","article-title":"Budesonide prolongs time to relapse in ileal and ileocaecal Crohn\u2019s disease. A placebo controlled one year study","volume":"39","author":"Lofberg","year":"1996","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2004.02.070_BIB4","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3109\/00365529509096316","article-title":"Disease activity courses in a regional cohort of Crohn\u2019s disease patients","volume":"30","author":"Munkholm","year":"1995","journal-title":"Scand J Gastroenterol"},{"key":"10.1053\/j.gastro.2004.02.070_BIB5","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S0016-5085(98)70420-2","article-title":"Clinical course of colorectal Crohn\u2019s disease","volume":"114","author":"Lapidus","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2004.02.070_BIB6","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJM198005013021801","article-title":"Treatment of Crohn\u2019s disease with 6-mercaptopurine. A long-term, randomized, double-blind study","volume":"302","author":"Present","year":"1980","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2004.02.070_BIB7","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1136\/gut.37.5.674","article-title":"A controlled double blind study of azathioprine in the management of Crohn\u2019s disease","volume":"37","author":"Candy","year":"1995","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2004.02.070_BIB8","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0140-6736(96)90402-X","article-title":"Long-term follow-up of patients with Crohn\u2019s disease treated with azathioprine or 6-mercaptopurine","volume":"347","author":"Bouhnik","year":"1996","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2004.02.070_BIB9","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199502023320503","article-title":"Methotrexate for the treatment of Crohn\u2019s disease. The North American Crohn\u2019s Study Group Investigators","volume":"332","author":"Feagan","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2004.02.070_BIB10","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJM200006013422202","article-title":"A comparison of methotrexate with placebo for the maintenance of remission in Crohn\u2019s disease. North American Crohn\u2019s Study Group Investigators","volume":"342","author":"Feagan","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2004.02.070_BIB11","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/0016-5085(94)90398-0","article-title":"Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease","volume":"106","author":"Breese","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2004.02.070_BIB12","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1365-2249.1993.tb05997.x","article-title":"Enhanced secretion of tumour necrosis factor-alpha IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn\u2019s disease","volume":"94","author":"Reinecker","year":"1993","journal-title":"Clin Exp Immunol"},{"key":"10.1053\/j.gastro.2004.02.070_BIB13","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1136\/jcp.46.8.757","article-title":"Cytokines in stools of children with inflammatory bowel disease or infective diarrhoea","volume":"46","author":"Nicholls","year":"1993","journal-title":"J Clin Pathol"},{"key":"10.1053\/j.gastro.2004.02.070_BIB14","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1046\/j.1365-2036.2001.00956.x","article-title":"Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn\u2019s disease","volume":"15","author":"Cornillie","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2004.02.070_BIB15","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1053\/gast.2001.24042","article-title":"An engineered human antibody to TNF (CDP571) for active Crohn\u2019s disease","volume":"120","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2004.02.070_BIB16","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","article-title":"Etanercept for active Crohn\u2019s disease","volume":"121","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2004.02.070_BIB17","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa020732","article-title":"Natalizumab for active Crohn\u2019s disease","volume":"348","author":"Ghosh","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2004.02.070_BIB18","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0016-5085(99)70224-6","article-title":"Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn\u2019s ileocolitis","volume":"116","author":"Baert","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2004.02.070_BIB19","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1053\/gast.2001.28702","article-title":"Infliximab induces apoptosis in monocytes from patients with chronic active Crohn\u2019s disease by using a caspase-dependent pathway","volume":"121","author":"Lugering","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2004.02.070_BIB20","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1136\/gut.50.2.206","article-title":"Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn\u2019s disease","volume":"50","author":"ten Hove","year":"2002","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2004.02.070_BIB21","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/S0016-5085(03)00382-2","article-title":"Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn\u2019s disease","volume":"124","author":"Van den Brande","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2004.02.070_BIB22","doi-asserted-by":"crossref","first-page":"A101","DOI":"10.1016\/S0016-5085(03)80497-3","article-title":"Effects of Infliximab on apoptosis and reverse signaling of monocytes","volume":"124","author":"Ringheam","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2004.02.070_BIB23","doi-asserted-by":"crossref","first-page":"A-486","DOI":"10.1016\/S0016-5085(03)82462-9","article-title":"Infliximab induces death of human monocytes in vitro and in the Thp-1-Scid-mice model","volume":"124","author":"Shen","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2004.02.070_BIB24","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0140-6736(93)91375-V","article-title":"Tumour-necrosis-factor antibody treatment in Crohn\u2019s disease (letter)","volume":"342","author":"Derkx","year":"1993","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2004.02.070_BIB25","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0140-6736(94)90628-9","article-title":"Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis","volume":"344","author":"Elliott","year":"1994","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2004.02.070_BIB26","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0016-5085(95)90277-5","article-title":"Treatment of Crohn\u2019s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)","volume":"109","author":"van Dullemen","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2004.02.070_BIB27","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn\u2019s disease. Crohn\u2019s Disease cA2 Study Group","volume":"337","author":"Targan","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2004.02.070_BIB28","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn\u2019s disease","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2004.02.070_BIB29","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/j.1572-0241.2001.03612.x","article-title":"Infliximab for Crohn\u2019s disease in clinical practice at the Mayo Clinic","volume":"96","author":"Ricart","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2004.02.070_BIB30","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1046\/j.1445-5994.2001.00039.x","article-title":"Early Australian experience with infliximab, a chimeric antibody against tumour necrosis factor-alpha, in the treatment of Crohn\u2019s disease","volume":"31","author":"Mortimore","year":"2001","journal-title":"Intern Med J"},{"issue":"Suppl 1","key":"10.1053\/j.gastro.2004.02.070_BIB31","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1002\/ibd.3780070505","article-title":"Efficacy and safety of repeated infliximab infusions for Crohn\u2019s disease","volume":"7","author":"Cohen","year":"2001","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2004.02.070_BIB32","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/00054725-200203000-00002","article-title":"Infliximab treatment for Crohn\u2019s disease","volume":"8","author":"Hommes","year":"2002","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2004.02.070_BIB33","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1155\/2002\/379307","article-title":"Clinical experience with infliximab for Crohn\u2019s disease","volume":"16","author":"Sample","year":"2002","journal-title":"Can J Gastroenterol"},{"key":"10.1053\/j.gastro.2004.02.070_BIB34","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1046\/j.1365-2036.2002.01268.x","article-title":"Effects of anti-tumour necrosis factor-alpha therapy on the quality of life in Crohn\u2019s disease","volume":"16","author":"van Balkom","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2004.02.070_BIB35","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S1590-8658(02)80038-X","article-title":"Infliximab in treatment of Crohn\u2019s disease","volume":"34","author":"Ardizzone","year":"2002","journal-title":"Dig Liver Dis"},{"key":"10.1053\/j.gastro.2004.02.070_BIB36","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1111\/j.1572-0241.2002.05991.x","article-title":"Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn\u2019s disease","volume":"97","author":"Vermeire","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2004.02.070_BIB37","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1053\/gast.2002.35390","article-title":"Predictors of response to infliximab in patients with Crohn\u2019s disease","volume":"123","author":"Parsi","year":"2002","journal-title":"Gastroenterology"},{"issue":"Suppl","key":"10.1053\/j.gastro.2004.02.070_BIB38","doi-asserted-by":"crossref","first-page":"A-523","DOI":"10.1016\/S0016-5085(03)82646-X","article-title":"Azathioprine and smoking status in Crohn\u2019s disease predict response to infliximab","volume":"124","author":"Arnott","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2004.02.070_BIB39","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0016-5085(99)70332-X","article-title":"Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn\u2019s disease","volume":"117","author":"Rutgeerts","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2004.02.070_BIB40","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1053\/j.gastro.2003.11.014","article-title":"Comparison of scheduled and episodic treatment strategies of infliximab in Crohn\u2019s disease","volume":"126","author":"Rutgeerts","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2004.02.070_BIB41","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S0016-5085(99)70005-3","article-title":"Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn\u2019s disease","volume":"116","author":"D\u2019haens","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2004.02.070_BIB42","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohn\u2019s disease","volume":"340","author":"Present","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2004.02.070_BIB43","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn\u2019s disease","volume":"350","author":"Sands","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2004.02.070_BIB44","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0002-9270(02)05909-9","article-title":"Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn\u2019s disease","volume":"98","author":"Van Assche","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2004.02.070_BIB45","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1046\/j.1365-2036.2003.01427.x","article-title":"Response of fistulating Crohn\u2019s disease to infliximab treatment assessed by magnetic resonance imaging","volume":"17","author":"Bell","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2004.02.070_BIB46","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10350-004-6111-6","article-title":"Endosonographic evidence of persistence of Crohn\u2019s disease-associated fistulas after infliximab treatment, irrespective of clinical response","volume":"45","author":"van Bodegraven","year":"2002","journal-title":"Dis Colon Rectum"},{"key":"10.1053\/j.gastro.2004.02.070_BIB47","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s10350-004-6611-4","article-title":"Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn\u2019s disease","volume":"46","author":"Topstad","year":"2003","journal-title":"Dis Colon Rectum"},{"key":"10.1053\/j.gastro.2004.02.070_BIB48","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1080\/gas.37.7.818.824","article-title":"A positive response to infliximab in Crohn disease","volume":"37","author":"Louis","year":"2002","journal-title":"Scand J Gastroenterol"},{"key":"10.1053\/j.gastro.2004.02.070_BIB49","first-page":"A2691","article-title":"Response to infliximab is decreased in the presence of intestinal strictures in patients with Crohn\u2019s disease","volume":"94","author":"Lichtenstein","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2004.02.070_BIB50","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1046\/j.1365-2036.2003.01672.x","article-title":"Response to infliximab is related to disease duration in paediatric Crohn\u2019s disease","volume":"18","author":"Lionetti","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2004.02.070_BIB51","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/sj.tpj.6500091","article-title":"Pharmacogenetic investigation of the TNF\/TNF-receptor system in patients with chronic active Crohn\u2019s disease treated with infliximab","volume":"2","author":"Mascheretti","year":"2002","journal-title":"Pharmacogenomics J"},{"key":"10.1053\/j.gastro.2004.02.070_BIB52","first-page":"509","article-title":"Response to infliximab treatment in Crohn\u2019s disease is not associated with mutations in the CARD15 (NOD2) gene","volume":"2","author":"Mascheretti","year":"2002","journal-title":"Pharmacogenomics J"},{"key":"10.1053\/j.gastro.2004.02.070_BIB53","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1053\/gast.2002.34172","article-title":"Belgian Group of Infliximab Expanded Access Program and Fondation Jean Dausset CEPH, Paris, France. NOD2\/CARD15 does not influence response to infliximab in Crohn\u2019s disease","volume":"123","author":"Vermeire","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2004.02.070_BIB54","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1053\/gast.2001.23966","article-title":"ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn\u2019s disease","volume":"120","author":"Taylor","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2004.02.070_BIB55","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0016-5085(03)80012-4","article-title":"A polymorphism in IgG Fc receptor gene FCGR3A is associated with biological response to infliximab in Crohn disease","volume":"124","author":"Louis","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2004.02.070_BIB56","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1111\/j.1572-0241.2002.05689.x","article-title":"Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn\u2019s disease","volume":"97","author":"Esters","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2004.02.070_BIB57","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn\u2019s disease","volume":"348","author":"Baert","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2004.02.070_BIB58","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1053\/gast.2003.50145","article-title":"Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn\u2019s disease","volume":"124","author":"Farrell","year":"2003","journal-title":"Gastroenterology"},{"issue":"Suppl","key":"10.1053\/j.gastro.2004.02.070_BIB59","first-page":"A44","article-title":"Infliximab in steroid dependent Crohn\u2019s disease patients treated with azathioprine or 6-MP a randomized double-blind placebo-controlled trial","volume":"52","author":"Lemann","year":"2003","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2004.02.070_BIB60","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1111\/j.1572-0241.2000.02261.x","article-title":"Annual cost of care for Crohn\u2019s disease","volume":"95","author":"Feagan","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2004.02.070_BIB61","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1572-0241.2000.01779.x","article-title":"The cost of hospitalization in Crohn\u2019s disease","volume":"95","author":"Cohen","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2004.02.070_BIB62","first-page":"151","article-title":"Infliximab decreases resource use among patients with Crohn\u2019s disease","volume":"35","author":"Rubenstein","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2004.02.070_BIB63","first-page":"OP-G-223","article-title":"Infliximab use in Crohn\u2019s disease","volume":"A45","author":"Jewell","year":"2003","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2004.02.070_BIB64","first-page":"OP-G-269","article-title":"Estimating cost-effectiveness of maintenance infliximab for chronic active Crohn\u2019s disease from accent 1","volume":"A54","author":"Wong","year":"2003","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2004.02.070_BIB65","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.3109\/00365529709002993","article-title":"Inflammatory bowel diseases","volume":"32","author":"Blomqvist","year":"1997","journal-title":"Scand J Gastroenterol"},{"key":"10.1053\/j.gastro.2004.02.070_BIB66","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1002\/ibd.3780070507","article-title":"Infliximab for patients with refractory ulcerative colitis","volume":"7","author":"Chey","year":"2001","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2004.02.070_BIB67","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1111\/j.1572-0241.2002.06026.x","article-title":"Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis","volume":"97","author":"Su","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2004.02.070_BIB68","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/00054725-200105000-00001","article-title":"Infliximab in the treatment of severe, steroid-refractory ulcerative colitis","volume":"7","author":"Sands","year":"2001","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2004.02.070_BIB69","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1136\/gut.52.7.998","article-title":"Infliximab in moderately severe glucocorticoid resistant ulcerative colitis","volume":"52","author":"Probert","year":"2003","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2004.02.070_BIB70","doi-asserted-by":"crossref","first-page":"A-62","DOI":"10.1016\/S0016-5085(03)80304-9","article-title":"Infliximab for acute severe ulcerative colitis","volume":"124","author":"Ochsenkuhn","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2004.02.070_BIB71","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1046\/j.1365-2036.2003.01686.x","article-title":"Infliximab for refractory ulcerative colitis or indeterminate colitis","volume":"18","author":"Gornet","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2004.02.070_BIB72","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1046\/j.1365-2036.2003.01739.x","article-title":"Infliximab in the treatment of medically refractory indeterminate colitis","volume":"18","author":"Papadakis","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2004.02.070_BIB73","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1111\/j.1572-0241.2003.07581.x","article-title":"Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease","volume":"98","author":"Regueiro","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2004.02.070_BIB74","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1001\/archsurg.135.5.564","article-title":"Twenty cases of peristomal pyoderma gangrenosum","volume":"135","author":"Sheldon","year":"2000","journal-title":"Arch Surg"},{"key":"10.1053\/j.gastro.2004.02.070_BIB75","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1001\/archopht.1997.01100150063010","article-title":"Uveitis associated with inflammatory bowel disease compared with uveitis associated with spondyloarthropathy","volume":"115","author":"Lyons","year":"1997","journal-title":"Arch Ophthalmol"},{"key":"10.1053\/j.gastro.2004.02.070_BIB76","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0161-6420(03)00406-8","article-title":"Infliximab in the treatment of refractory posterior uveitis","volume":"110","author":"Joseph","year":"2003","journal-title":"Ophthalmology"},{"key":"10.1053\/j.gastro.2004.02.070_BIB77","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1016\/S0161-6420(02)01292-7","article-title":"Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis","volume":"109","author":"El-Shabrawi","year":"2002","journal-title":"Ophthalmology"},{"key":"10.1053\/j.gastro.2004.02.070_BIB78","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1002\/1529-0131(200106)44:6<1411::AID-ART235>3.0.CO;2-O","article-title":"Etanercept therapy in children with treatment-resistant uveitis","volume":"44","author":"Reiff","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.gastro.2004.02.070_BIB79","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/S0140-6736(00)03239-6","article-title":"Crohn\u2019s disease associated with spondyloarthropathy","volume":"356","author":"Van den","year":"2000","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2004.02.070_BIB80","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/art.511","article-title":"Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy","volume":"46","author":"Van Den Bosch","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.gastro.2004.02.070_BIB81","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","article-title":"Treatment of active ankylosing spondylitis with infliximab","volume":"359","author":"Braun","year":"2002","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2004.02.070_BIB82","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJMoa012664","article-title":"Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha","volume":"346","author":"Gorman","year":"2002","journal-title":"N Engl J Med"},{"issue":"suppl","key":"10.1053\/j.gastro.2004.02.070_BIB83","first-page":"A469","article-title":"A randomised placebo-controlled trial of CDP571, a humanized monoclonal antibody to TNF-A in patients with moderate to severe Crohn\u2019s disease","volume":"124","author":"Sandborn","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2004.02.070_BIB84","doi-asserted-by":"crossref","first-page":"A61","DOI":"10.1016\/S0016-5085(03)80301-3","article-title":"CDP870, a humanized anti-TNF antibody fragment induces clinical response with remission in patients with active Crohn\u2019s disease","volume":"124","author":"Schreiber","year":"2003","journal-title":"Gastroenterology"},{"issue":"suppl","key":"10.1053\/j.gastro.2004.02.070_BIB85","first-page":"A4","article-title":"CDP870, a pegylated humanized anti-TNF antibody fragment offers particular benefit to Crohn\u2019s disease patients with elevated C-reactive protein","volume":"52","author":"Schreiber","year":"2003","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2004.02.070_BIB86","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","article-title":"Etanercept for active Crohn\u2019s disease","volume":"121","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2004.02.070_BIB87","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1046\/j.1365-2036.2003.01414.x","article-title":"Treatment of active Crohn\u2019s disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor)","volume":"17","author":"Rutgeerts","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2004.02.070_BIB88","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1084\/jem.173.3.699","article-title":"Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes","volume":"173","author":"Sampaio","year":"1991","journal-title":"J Exp Med"},{"key":"10.1053\/j.gastro.2004.02.070_BIB89","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/gut.50.2.196","article-title":"Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn\u2019s disease","volume":"50","author":"Bauditz","year":"2002","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2004.02.070_BIB90","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/S0016-5085(99)70276-3","article-title":"Thalidomide therapy for patients with refractory Crohn\u2019s disease","volume":"117","author":"Ehrenpreis","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2004.02.070_BIB91","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0016-5085(99)70277-5","article-title":"An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn\u2019s disease","volume":"117","author":"Vasiliauskas","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2004.02.070_BIB92","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1046\/j.1365-2036.2002.01273.x","article-title":"An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn\u2019s disease","volume":"16","author":"Sabate","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2004.02.070_BIB93","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1053\/gast.2002.30770","article-title":"Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn\u2019s disease","volume":"122","author":"Hommes","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2004.02.070_BIB94","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00063-003-1282-9","article-title":"Suspected cases of severe side effects after infliximab (Remicade) in Germany","volume":"98","author":"Andus","year":"2003","journal-title":"Med Klin"},{"key":"10.1053\/j.gastro.2004.02.070_BIB95","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/j.gastro.2003.10.047","article-title":"The safety profile of infliximab in patients with Crohn\u2019s disease","volume":"126","author":"Colombel","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2004.02.070_BIB96","first-page":"G3174","article-title":"Delayed hypersensitivity to infliximab (Remicade\u00aere-infusion after 2\u20134 year interval without treatment","volume":"116","author":"Hanauer","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2004.02.070_BIB97","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","article-title":"Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure","volume":"107","author":"Chung","year":"2003","journal-title":"Circulation"},{"key":"10.1053\/j.gastro.2004.02.070_BIB98","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2165\/00063030-200216030-00003","article-title":"Therapeutic approaches in multiple sclerosis","volume":"16","author":"Wiendl","year":"2002","journal-title":"BioDrugs"},{"key":"10.1053\/j.gastro.2004.02.070_BIB99","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0016-5085(03)00701-7","article-title":"Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn\u2019s disease","volume":"125","author":"Vermeire","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2004.02.070_BIB100","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508504004573?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508504004573?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,3,9]],"date-time":"2019-03-09T16:19:30Z","timestamp":1552148370000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508504004573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5]]},"references-count":100,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2004,5]]}},"alternative-id":["S0016508504004573"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2004.02.070","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2004,5]]}}}